CoStasis Stops Bleeding At Hard And Soft Tissue Sites - Cohesion PMA Study
This article was originally published in The Gray Sheet
Executive Summary
Cohesion Technologies plans to file a premarket approval application this spring for its CoStasis surgical hemostat for treatment of bleeding in cardiovascular, hepatic, general and orthopedic surgery procedures, the firm announced Jan. 14.
You may also be interested in...
Cohesion's CoStasis Surgical Hemostat To Ship In July, Gains FDA Approval
Tyco International's U.S. Surgical unit will market Cohesion Technologies' CoStasis liquid surgical hemostat. Shipments are expected to begin in early July.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.